KẾT QUẢ ĐIỀU TRỊ VÀ MỘT SỐ YẾU TỐ LIÊN QUAN ĐẾN ĐÁP ỨNG HÓA TRỊ Ở BỆNH NHÂN U LYMPHO TẾ BÀO ÁO TẠI VIỆN HUYẾT HỌC – TRUYỀN MÁU TRUNG ƯƠNG GIAI ĐOẠN 2021–2024

Abstract

Objective: To analyze treatment outcomes and identify factors associated with chemotherapy response in patients with mantle cell lymphoma (MCL) treated at the National Institute of Hematology and Blood Transfusion (NIHBT) during 2021–2024. Methods: This was a case series study with both retrospective and prospective data collection. A total of 57 newly diagnosed MCL patients were enrolled, of whom 46 met the criteria for chemotherapy and were evaluated for treatment response. Data were analyzed using SPSS 20.0 with appropriate statistical tests (p < 0.05). Results: The overall response rate after three chemotherapy cycles was 86.9%, with a complete response (CR) rate of 23.9%. At the end of treatment, CR increased to 54.6%. Mortality due to infection and disease progression accounted for 22.7%. The R-CHOP/R-DHAP regimen showed the highest CR rate (63.3%). Clinical stage, MIPI-c risk group, Ki-67 index, and LDH levels showed a trend toward influencing treatment outcomes, although the differences were not statistically significant. Conclusion: Chemotherapy demonstrates high efficacy in MCL patients, particularly with the R-CHOP/R-DHAP regimen. Prognostic factors such as MIPI-c, Ki-67, and LDH should be considered when tailoring treatment to improve clinical outcomes.